Alumis (ALMS) Other Accumulated Expenses (2023 - 2025)

Alumis' (ALMS) quarterly Other Accumulated Expenses came in at $81000.0 in Q4 2025, down 48.73% year-on-year from $158000.0 in Q4 2024, and up 28.57% on a QoQ basis from $63000.0 in Q3 2025.

Alumis (ALMS) Other Accumulated Expenses (2023 - 2025) Analysis & Trends

Alumis (ALMS) has 3 years of Other Accumulated Expenses data on file, last reported at $81000.0 in Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 48.73% year-over-year to $81000.0 in Q4 2025; TTM through Dec 2025 was $81000.0, a 48.73% decrease from a year earlier, with the FY2025 full-year figure at $81000.0, down 48.73% from the prior year.
  • Other Accumulated Expenses for Q4 2025 stood at $81000.0, up from $63000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ALMS reached as high as $550000.0 in Q2 2024 and fell as low as $63000.0 in Q3 2025.
  • Historically, Other Accumulated Expenses has averaged $262625.0 across 3 years, with a median of $253000.0 in 2024.
  • Across the five-year window, Other Accumulated Expenses tumbled 61.37% in 2024 and declined 18.18% in 2025, its largest moves.
  • Year by year, Other Accumulated Expenses stood at $409000.0 in 2023, then tumbled by 61.37% to $158000.0 in 2024, then sank by 48.73% to $81000.0 in 2025.
  • Per Business Quant data, the three most recent Other Accumulated Expenses figures were $81000.0 in Q4 2025, $63000.0 in Q3 2025, and $348000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn -
4 BeOne Medicines 469.11 Bn 464.32 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.03 Bn 115.78 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.13 Bn 61.37 Bn 3.31 Bn
7 Belite Bio 63.44 Bn 63.44 Bn -
8 Argenx Se 55.97 Bn 50.78 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 Alumis 2.43 Bn 2.12 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 81,000.00
Sep 30, 2025 63,000.00
Jun 30, 2025 348,000.00
Mar 31, 2025 415,000.00
Dec 31, 2024 158,000.00
Sep 30, 2024 77,000.00
Jun 30, 2024 550,000.00
Dec 31, 2023 409,000.00